Habilitation Dr. Daunderer - Klinische Erfahrungen
mit Antidot 4-DMAP
Table of Contents
Introduction
Chemical and Physical Properties
Quantitative Composition of the Injection Solution
Information about the Analytics
Quality Control
Toxicological Properties
Teratogenic Properties
Pharmacological Properties
Dosage and Mode of Application
Compatibility
Clinical
Examinations
Pharmacokinetics
4-DMAP INTRODUCTION
This documentation includes the description of 4-DMAP,
a preparation for the treatment of poisonings with cyanides, hydrocyanic acid
and nitriles, also possibly of poisonings with hydrogen sulphide.
The experimental examinations with animals and the
basic clinical experiments were conducted almost exclusively at the
Pharmakologisches Institut der Universität München (Pharmacological Institute
of the
treatment of cyanide poisoning for more than 10
years. The results of relevant
examinations have been recorded in numerous publications and scientific reports
for the "Sanitäts-Lehr- und Arbeitsgruppe ABC-Schutz ("Medical,
Eductional and Working Group ABC Protection").
In the following,
4-DMAP is always understood as 4-Dimethylamino-phenol hydrochloride.
Chemical and Physical Properties
4-DMAP forms snow-white crystals which are very readily soluble in water and which melt at
345. ]°C. 4-DMAP is rapidly oxidized in
an aqueous solution giving rise to intensively brown to blackish-brown coloured
derivatives due to polycondensation of the corresponding quinone.
The determination of the decomposition kinetics of
4-DMAP solutions
at 20°C and a pH value of 5.0, the Standard of the
active substance drops from 100 % to 96.8 % in the course of 8.2 years. In this
respect, a 4-DMAP solution can be described äs remarkably stable.
See also:
C. Bannert and K. Weger: 4-Dimethylaminophenol für
intramuskuläre
des Sanitäts- und Gesundheitswesens der Bundeswehr
München 1973 (Academy of the Sanitary and Public Health Service of the Federal
Army Munich 1973)
Quantitative Composition of the Injection Solution
5 ml contain:
2500 mg
4-Dimethylaminophenol hydrochloride 2,5 mg Sodium-disulfite, ^28205 0,5
mg Na EDTA
£1
pH = 4.7, reached
with app. 10 mg
Sodium-hydrogencarbonate
A patent for the procedure of the preparation of stable
aqueous 4-DMAP solutions has been applied for at the Bundespatentamt (Federal Patent Office) in
Aqueous solutions of 4-DMAP give, in the presence of
oxygen and at pH values above 3.0, intensive discolourations within 12 hours.
The rate of oxidationprocesses hereby taking place and which are followed by
colour producing polymerisation processes, is determined by the degree of
dissociation of the proton of the phenolic OH-group according to the following
equation:
Upon raising the pH value to above 3,0, preferably
above 5,0, which is necessary for
application technical reasons, the oxidation of 4-DMAP in aqueous solution is
already effected by traces of oxygen dissolved.
The complete elimination of oxygen by use of inert gas
while filling 4-DMAP solutions into ampoules is ensured only by the addition of
effective antioxidant agents because of the subsequent contact with air which
is technically only difficult to avoid during the form-turning of the ampoules
or phials. This aspect forms the basis
of the aforesaid patent application.
Information about the Analytics:
1. 4-DMAP
Pure Substance Determined are:
a) Melting point
b) Content: by
titration
by elementary analysis
c) I. R. -spectrum
d) Chromatogram
e) Drying loss
f) Sulphate ash
g) Heavy metals
2. 4-DMAP
Ampoules
a) Identity
b) pH value
c) Drying residue
In case of poisonings with hydrocyanic acid, cyanides and nitriles, also possibly in case
of poisonings with hydrogen sulphide.
Quality Control:
1. Sterility
The quality controls of 4-DMAP are executed according
to the Standards and terms of the DAB VII - Deutsches
Arzneibuch VII (German Pharma-copoeia VII).
The examination of the sterility is carried out with
4 filling units (ampoules) at the beginning of the
sterilising filtration, 4 filling units in the middle of the sterilising
filtration and 4 filling units at the end of the sterilising filtration.
In detail, the procedure of the proof of sterility is
as follows:
10-15 ml of Standard-I-nutrient bouillon (Merck, Art.
No.7882) is incubated with 3 ml of 4-DMAP feed, to be examined, at 37°C for 6
days. Any turbidity must not occur.
Furthermore, a plate test is carried out äs a control:
a) Standard-I-N-agar for the detection of particular
germs
b) Sabouraud-glucose 2 % agar for the growing and
Isolation of pathogenic fungi and yeasts and
c) Thioglycolate bouillon according to USP XVIII (Merck,
Art.No. 8190 and 8191) for the test on anaerobic microorganisms
is poured into sterile Petri dishes. The 4-DMAP feed to be examined is spread lege
artis into these culture media.
The culture media are incubated
a) at 37°C and
b) at 25°C for 6
days.
According to the observations made so far, an aqueous
solution of 4-DMAP proves itself to be autosterile in a therapeutically
designated concentration.
2 . Absence of Pyrogens
For toxicological reasons, the execution of the
pyrogenic test on rabbits according to the regulations of the DAB VII -
Deutsches Arzneibuch VII (German
Pharmacopoeia VII) cannot be realized with an adequate volume
of the 4-DMAP solution.
Toxicological Properties:
1. Acute toxicity:
According to the investigations of N. Weger et al. ,
the LD for
0 U
dogs is 26 mg/kg of animal, whereby about 85 % of ferrihaemoglobin
(methaemoglobin) is formed. The animals
die of anoxia because only 15 % of the haemoglobin is available for the
transport of oxygen. With a ferrihaemoglobin content under 80 % of the total
haemoglobin, all the animals survive.
The therapeutical dose of 3-5 mg of 4-DMAP/kg of human
being oxidizes only 30-50 % of the haemoglobin to ferri-haemoglobin.
2. Chronic
toxicity:
With regard to the application of 4-DMAP according to regulations,
the examination of the active substance under the conditions of the chronic
toxicity is not necessary. Despite this,
in the dog experiment, 3 mg of 4-DMAP/kg of animal was intravenously
applied twice a week during a period of 13 weeks. This dose oxidizes 35 % of the haemoglobin,
but does not cause changes, either
macroscopically or microscopically, on the liver, spieen, kidney, heart, on the blood count or transaminases and
creatinine.
See also:
M. Kiese,
L. Scinicz, N. Thiel and N.
Weger: Wirkung des 4-Dimethyl-
aminophenols und
4-Aminophenols auf Organe von Hunden und Ratten; scientific report from the
Pharmakologische Institut der Universität München 1973 (Pharmacological
Institute of the University of Munich 1973).
Teratogenic Properties:
Examinations with 4-DMAP for effects which are
detrimental to the cells of propagation have not been carried out in view of
the range of indications of this active substance.
Pharmacological Properties:
The detoxification of cyanides, hydrocyanic acid and
nitriles proceeds according to the following scheme:
Ist Step:
2+ 3+ 4-DMAP + haemoglobin (Fe -O
) ———> ferrihaemoglobin (Fe )
&
2nd Step:
3+ CN + ferrihaemoglobin (Fe ) N s ferrihaemoglobin-CN-
complex (Fe3+CN") 3rd Step:
CN + sodium thiosulphate —————> thiocyanate (SCN )
^ rhodanase
For the therapy of poisonings with cyanides,
hydrocyanic acid and nitriles, about 30 % of the haemoglobin must be oxidized
to ferrihaemoglobin. After an intravenous application of approx. 3 mg of 4-DMAP/kg of body weight, the
semi-maximum concentration of ferrihaemoglobin is reached within one minute,
the maximum concentration after 5-10 minutes.
The physiological reduction of ferrihaemoglobin to
haemoglobin can be observed already after 30 minutes, 10 % of the total haemoglobin still being
present äs ferrihaemoglobin in the human being after approx. 4 hours after the
application.
In case of an overdosage of 4-DMAP, the reduction
process can be shortened to 30-15 minutes by an intravenous application of 2-4
mg of o-toluidine blue/ kg of body weight.
After an intravenous injection of 4-DMAP,
disorders, either in the coronary
circulation System or in the carbohydrate and protein metabolism, are not
observed. Heinz inner bodies are not found.
The activity of the transaminases remains unchanged.
After the conversion of the haemoglobin-cyanide
complex into the ferrihaemoglobin-cyanide complex by 4-DMAP, the detoxification
of the cytochrome oxidase blocked by the cyanide must be completed by high
doses of sodium thiosulphate. That
means, in a second step of the therapy, the cyanide is converted into the'
relatively non-toxic thiocyanate with the help of the endogenic rhodanase. This secondary detoxification process is
decisively accelerated by intravenous administrations of 50-100 mg of sodium
thiosulphate/kg of body weight. Thiocyanate
is excreted up to 80 % in the urine. Ferrihaemoglobin is physio-logically
reduced to haemoglobin.
See also:
N. Weger:
Therapie der Blausäurevergiftung durch Ferrihämoglobin-bildung;
Habilitations-Thesis from the Pharmakologische Institut der Universität München
1969 (Pharmacological Institute of the University Munich 1969).
N. Weger:
Aminophenole als Blausäureantidote; Arch.
Toxikol., 2A (1968), 49-50.
P. Eyer, M. Kiese, G. Lipowsky and N. Weger: Reactions
of 4-Dimethyl-aminophenol with Hemoglobin, and autoxidation of
4-Dimethylamino-phenol; Chem.-Biol. Interactions, Q_ (1974), 41-59.
M. Kiese, R.
Klimmek, L. Szinicz and N. Weger: Wirkung von
4-Dimethyl-aminophenol und Co-Histidin auf Atmung, Kreislauf und verschiedene Parameter des
Blutes bei Beagle Hunden nach akuter CyanidVergiftung; Scientific Report from
the Pharmakologische Institut der Universität München 1974 (Pharmacological
Institute of the University of Munich 1974).
M. Kiese, R.
Klimmek, L. Szinicz and N. Weger: Wirkung von 4-Dimethyl-aminophenol auf
Atmung, Kreislauf und verschiedene Parameter des Blutes bei Beagle Hunden;
Scientific Report from the Pharmakologische Institut der Universität München
1974 (Pharmacological Institute of the University of Munich 1974).
Dosage and Mode of Application:
After the diagnosis of a poisoning with hydrocyanic
acid, cyanides or nitriles, 3-4 mg of 4-DMAP/kg of body weight is
immediately injected intravenously within 30 seconds, that means: For an
adult, approximately l ampoule of
5 ml containing 250 mg of active substance.
Subsequently,
100-500 mg of sodium thiosulphate/kg of body weight is infused through
the same needle.
See also:
N. Weger:
Cyanidvergiftung und Therapie;
Wehrmed. Monats sehr. , 19 (1975), 6-11.
M. Daunderer, H.
Theml and N. Weger: Behandlung der Blausäurevergiftung mit
4-Dimethylaminophenol (4-DMAP); Med.Klin. , 69 (1974), 1626-1631
Compatibility:
In the investigations with the animal äs well äs in
the application in man, 4-DMAP does not show any effect on the blood pressure
and the flow velocity in the blood vessels.
Wenn applied according to the regulations, no other
Symptoms occured besides the cyanosis (formation of ferrihaemoglobin) to be
expected.
The effect of 4-DMAP on newbornes and infants has not
been investigated. Since the methaemoglobin reductase is not yet fully
effective in newborns, there is the danger of a long lasting
methaemoglobinemia.
4-DMAP does not cause any disorders in the
carbohydrate and protein metabolism. The antidote does not form Heinz inner
bodies and reacts inert in relation to the activity of the transaminases.
In experiments with dogs and rats, it was shown that a
dose of 30 mg of 4-DMAP/kg of animal does not cause pathological changes in the
kidney.
See also:
H. Offterdinger and N. Weger: Kreislauf und
Atmung bei Blausäurevergiftung und Therapie mit Ferrihämoglobinbildnern und Kobaltverbindungen;
Naunyn-Schmiedebergs Arch. Pharmak. , 264 (1969), 289.
N. Weger:
Therapie der Blausäure Vergiftung; Med.
Monatsschr., _23 (1969), 436-440.
M. Kiese, L.
Szinicz, N. Thiel and N. Weger:
Wirkung des 4-Dimethyl-
aminophenols und
4-Aminophenols auf Organe von Hunden und Ratten; scientific report from the
Pharmakologische Institut der Universität München 1973 (Pharmacological
Institute of the University of Munich 1973).
Clinical Examinations:
Because the extent of action of 4-DMAP regarding the
stoichiometric relations between the dose and the oxidative conversion of
haemoglobin to ferrihaemoglobin is clarified in detail, and, on the other hand,
because the detoxifying effect of ferrihaemoglobin on the cyanide-haemoglobin
complex is also very well known, the therapeutic scope of action of 4-DMAP,
when applied according to the regulations, can be exactly adjusted on this
basis without hesitation. In this respect, clinical examinations are not necessary in
case of provoked cyanide, hydrocyanic acid of nitrile poisonings, besides the
fact that clinical experiments äs defined in the regulations of the AMG -
Arzneimittelgesetz (law governing the manufacture and prescription of
medicines), under consideration of serious ethical aspects, cannot be realized.
See also:
M. Daunderer, H.
Theml and N. Weger: Behandlung der Blausäurevergiftung mit
4-Dimethylaminophenol (4-DMAP) Med. Klin., _69 (1974)
1616-1631
M. Kiese,
J.G. Schöber and N. Weger: Versuche
am Menschen zur Kinetik der Ferrihämoglobinbildung durch Aminophenole und
Nitrit; Naunyn-Schmiedebergs Arch. Pharmak., 260 (1968), 152.
M. Kiese, N.
Weger: The Treatment of Experimental Cyanide Poisoning
by Hemiglobin
Formation; Archiv für Toxikologie, 2l_
(1965), 89-100.
M. Kiese
and N. Weger: Hämiglobinbildung zur Behandlung der Cyanid-
Vergiftung;
Naunyn-Schmiedebergs Arch.
Pharmak., 250
(1965), 263,
M. Kiese, N.
Weger: Formation of Ferrihaemoglobin with Aminophenole in the Human for the
Treatment of Cyanide Poisoning; Europ. J. Pharmacology, 7 (1969),
97-105.
Pharmacokinetics:
4-DMAP is excreted through the kidneys. In the average, 16 % of a dose administered intravenously is
eliminated with the urine within 8 hours.
The following products of metabolism were detected äs
metabolites by means of radioactively marked 4-DMAP i
4-Methylaminophenol, quinone, hydroquinone,
formaldehyde, dimethylamine, and a blue äs well äs a yellow pigment of un-known
constitution.
See also:
W. Lörcher: Optimale Konzentration von
Ferrihämoglobin zur Behandlung
der
Blausäurevergiftung; Inaugural-Dissertation - Tierärztliche Hochschule der
Ludwig-Maximilians-Universität München 1973 (Veterinary Faculty of the
Ludwig-Maximilian University of Munich 1973).